MARKET

VTVT

VTVT

VTV THERAPEUTICS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.770
+0.040
+1.47%
Closed 17:23 02/19 EST
OPEN
2.730
PREV CLOSE
2.730
HIGH
2.946
LOW
2.520
VOLUME
644.29K
TURNOVER
--
52 WEEK HIGH
4.230
52 WEEK LOW
1.230
MARKET CAP
165.93M
P/E (TTM)
-4.6822
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of VTVT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

VTVT News

  • VTV Therapeutics 'Close To The Finish Line' On What FDA, Diabetes Patients Want: An Adjunct Therapy To Insulin
  • Benzinga.20h ago
  • vTv Therapeutics: A Promising Small Molecule Drug Discovery Pick For 2020
  • Seeking Alpha - Article.2d ago
  • Catalyst Biosciences Results Positive, And Other News: The Good, Bad And Ugly Of Biopharma
  • Seeking Alpha - Article.02/11 18:24
  • UAA, DBD among premarket losers
  • Seeking Alpha - Article.02/11 14:14

More

Industry

Biotechnology & Medical Research
+1.01%
Pharmaceuticals & Medical Research
+0.22%

Hot Stocks

Name
Price
%Change

About VTVT

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
More

Webull offers vTv Therapeutics Inc (VTVT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.